Read Full Article
- Sanofi is buying Belgian biotech Ablynx for $4.8 billion.
- Ablynx had recently rejected a rival company, Novo Nordisk, after it bid $3.1 billion on the blood-disease drug developer.
- It's Sanofi's second deal this month after it picked up Bioverativ in an $11.6 billion deal...
In the News,
With Ablynx, we continue to advance the strategic transformation of our research and development, expanding our late-stage pipeline and strengthening our platform for growth in rare blood disorders.